CeriBell (CBLL) Projected to Post Quarterly Earnings on Tuesday

CeriBell (NASDAQ:CBLL - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Tuesday, February 11th. Analysts expect the company to announce earnings of ($0.32) per share for the quarter.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by ($1.03). The business had revenue of $17.20 million during the quarter, compared to analyst estimates of $17.06 million. On average, analysts expect CeriBell to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CeriBell Trading Down 5.9 %

Shares of CeriBell stock traded down $1.34 on Friday, reaching $21.27. The stock had a trading volume of 151,600 shares, compared to its average volume of 181,344. The stock's 50 day moving average price is $25.09. CeriBell has a 1 year low of $18.69 and a 1 year high of $32.75.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on CBLL shares. Bank of America assumed coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set a "buy" rating and a $32.00 price target for the company. William Blair assumed coverage on CeriBell in a research report on Tuesday, November 5th. They set an "outperform" rating for the company. TD Cowen raised their price target on CeriBell from $31.00 to $36.00 and gave the company a "buy" rating in a report on Monday, December 9th. Canaccord Genuity Group assumed coverage on CeriBell in a report on Tuesday, November 5th. They set a "buy" rating and a $30.00 price objective for the company. Finally, Canaccord Genuity Group raised their target price on shares of CeriBell from $31.00 to $33.00 and gave the company a "buy" rating in a research note on Monday, December 9th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $32.60.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.